Education
About Us
Working with TipRanks
Follow Us
Eli Lilly And Company (LLY)
:LLY
LLY Analyst Ratings
Strong Buy
17 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LLY Stock 12 Month Forecast
Average Price Target
$1,016.69
▲(32.74% Upside)
| Highest Price Target$1,190 | Average Price Target$1,017 | Lowest Price Target$835.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$835
Hold
9.01%
Upside
Downgraded
07/30/25
Eli Lilly's overall stock score reflects strong financial performance and a positive outlook from its recent earnings call, driven by significant product contributions and strategic investments. However, the high valuation and mixed technical signals suggest caution. The company's high leverage and potential regulatory hurdles also warrant careful monitoring.
Bernstein
$1,100
Buy
43.61%
Upside
Assigned
08/01/25
TD Cowen
$960
Buy
25.33%
Upside
Reiterated
07/31/25
Wells Fargo
$1,100
Buy
43.61%
Upside
Reiterated
07/31/25
Morgan Stanley
$1,135
Buy
48.18%
Upside
Reiterated
07/31/25
Goldman Sachs
$883
Buy
15.28%
Upside
Reiterated
07/31/25
Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings ProjectionsWe await full data at the EASD meeting in September. Ahead of this trial we had offered the following framing with respect to potential stock reactions: (1) Non-inferiority with little differentiation – stock down low-single-digits %; (2) Non-inferiority with trend towards superiority, but not statistically significant – stock flat to up small; 3) Superiority: stock up mid-single digits % +. In our view, this outcome is closest to #2 above (though we expect some investor debate on this, noting the stock is trading lower by ~2% pre-market). More importantly, this removes one of three overhangs, as focus for the stock now shifts to the 2Q earnings next week (Aug 7th) ahead of which there have been concerns given Novo Nordisk’s profit warning earlier this week.
Citi
$1,190
Buy
55.36%
Upside
Reiterated
07/30/25
Leerink Partners
―
Buy
―
Reiterated
07/29/25
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Eli Lilly & Co (NYSE: LLY) and Bausch + Lomb Corporation (NYSE: BLCO)We look forward to future trial updates. Separately, LLY anticipates the readout from another Jaypirca Ph3 trial, BRUIN CLL-313 vs. chemoimmunotherapy in treatment-naïve CLL/SLL, later in 2025, and expects global regulatory submissions after combining data from the two Ph3 studies. We model Jaypirca 2032E sales of $3.0B, 7% above cons’ $2.8B. Maintain OP on LLY shares.
Deutsche Bank
$1,010
Buy
31.86%
Upside
Reiterated
07/29/25
BMO Capital
$900→$920
Buy
20.11%
Upside
Reiterated
07/28/25
Jefferies
$1,057
Buy
38.00%
Upside
Reiterated
07/18/25
Guggenheim
$936→$942
Buy
22.98%
Upside
Reiterated
07/11/25
Bank of America Securities
$1,000
Buy
30.56%
Upside
Reiterated
07/09/25
J.P. Morgan
$1,100
Buy
43.61%
Upside
Reiterated
07/07/25
UBS
$1,050
Buy
37.08%
Upside
Reiterated
06/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$835
Hold
9.01%
Upside
Downgraded
07/30/25
Eli Lilly's overall stock score reflects strong financial performance and a positive outlook from its recent earnings call, driven by significant product contributions and strategic investments. However, the high valuation and mixed technical signals suggest caution. The company's high leverage and potential regulatory hurdles also warrant careful monitoring.
Bernstein
$1,100
Buy
43.61%
Upside
Assigned
08/01/25
TD Cowen
$960
Buy
25.33%
Upside
Reiterated
07/31/25
Wells Fargo
$1,100
Buy
43.61%
Upside
Reiterated
07/31/25
Morgan Stanley
$1,135
Buy
48.18%
Upside
Reiterated
07/31/25
Goldman Sachs
$883
Buy
15.28%
Upside
Reiterated
07/31/25
Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings ProjectionsWe await full data at the EASD meeting in September. Ahead of this trial we had offered the following framing with respect to potential stock reactions: (1) Non-inferiority with little differentiation – stock down low-single-digits %; (2) Non-inferiority with trend towards superiority, but not statistically significant – stock flat to up small; 3) Superiority: stock up mid-single digits % +. In our view, this outcome is closest to #2 above (though we expect some investor debate on this, noting the stock is trading lower by ~2% pre-market). More importantly, this removes one of three overhangs, as focus for the stock now shifts to the 2Q earnings next week (Aug 7th) ahead of which there have been concerns given Novo Nordisk’s profit warning earlier this week.
Citi
$1,190
Buy
55.36%
Upside
Reiterated
07/30/25
Leerink Partners
―
Buy
―
Reiterated
07/29/25
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Eli Lilly & Co (NYSE: LLY) and Bausch + Lomb Corporation (NYSE: BLCO)We look forward to future trial updates. Separately, LLY anticipates the readout from another Jaypirca Ph3 trial, BRUIN CLL-313 vs. chemoimmunotherapy in treatment-naïve CLL/SLL, later in 2025, and expects global regulatory submissions after combining data from the two Ph3 studies. We model Jaypirca 2032E sales of $3.0B, 7% above cons’ $2.8B. Maintain OP on LLY shares.
Deutsche Bank
$1,010
Buy
31.86%
Upside
Reiterated
07/29/25
BMO Capital
$900→$920
Buy
20.11%
Upside
Reiterated
07/28/25
Jefferies
$1,057
Buy
38.00%
Upside
Reiterated
07/18/25
Guggenheim
$936→$942
Buy
22.98%
Upside
Reiterated
07/11/25
Bank of America Securities
$1,000
Buy
30.56%
Upside
Reiterated
07/09/25
J.P. Morgan
$1,100
Buy
43.61%
Upside
Reiterated
07/07/25
UBS
$1,050
Buy
37.08%
Upside
Reiterated
06/27/25
Best Analysts Covering Eli Lilly & Co
1 Month
xxx
Success Rate
29/40 ratings generated profit
Average Return
+4.57%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.50% of your transactions generating a profit, with an average return of +4.57% per trade.
3 Months
xxx
Success Rate
31/42 ratings generated profit
Average Return
+10.27%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.81% of your transactions generating a profit, with an average return of +10.27% per trade.
1 Year
Success Rate
37/42 ratings generated profit
Average Return
+33.50%
reiterated a buy rating 9 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 88.10% of your transactions generating a profit, with an average return of +33.50% per trade.
2 Years
xxx
Success Rate
28/32 ratings generated profit
Average Return
+28.50%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +28.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LLY Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
1
4
8
10
7
Buy
62
60
66
65
44
Hold
3
4
3
7
6
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
67
69
78
82
57
Each month's total comprises the sum of three months' worth of ratings.
LLY Financial Forecast
LLY Stock Forecast FAQ
What is LLY’s average 12-month price target, according to analysts?
Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 1,016.69.
What is LLY’s upside potential, based on the analysts’ average price target?
Eli Lilly And Company has 32.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LLY a Buy, Sell or Hold?
Eli Lilly And Company has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.
What is Eli Lilly And Company’s price target?
The average price target for Eli Lilly And Company is 1,016.69. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,190.00 ,the lowest forecast is $835.00. The average price target represents 32.74% Increase from the current price of $765.95.
The highest analyst price target is $1,190.00 ,the lowest forecast is $835.00. The average price target represents 32.74% Increase from the current price of $765.95.
What do analysts say about Eli Lilly And Company?
Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of LLY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.